Augustine Ahenkorah
Psychiatric/Mental Health · Fairfax, VANPI 1376118182
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,217, more than ten times the $95 reported in 2023.
Across 74 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$310
- Lundbeck LLC$169
- Corium, LLC$152
- AbbVie$152
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
- Vanda Pharmaceuticals Inc.$134
- plus $646 from 16 others
What the payments were for
- Food & beverage$1,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $310 |
| Lundbeck LLC | 6 | $169 |
| Corium, LLC | 6 | $152 |
| AbbVie | 9 | $152 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $134 |
| Axsome Therapeutics, Inc. | 5 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Johnson & Johnson | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $47 |
| Alkermes, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bausch Health US, LLC | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| TMS Neurohealth Centers Inc. | 1 | $26 |
| Harmony Biosciences LLC | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Neuronetics, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $21 |
| Tris Pharma Inc | 1 | $14 |
How this compares
$1,699 in reported general payments places this provider in the 75th percentile of 1,003 psychiatric/mental health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 13 | $323 |
| Fluvoxamine Maleate | 14 | $165 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Fairfax
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.